Where does Xigen Inflammation Ltd. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Xigen Inflammation Ltd. ranks #22,052 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Xigen Inflammation Ltd. hold?

Xigen Inflammation Ltd. holds 13 US utility patents granted between 2015 and 2023, spanning 5 technology areas.

What is Xigen Inflammation Ltd.'s Innovation Score?

Xigen Inflammation Ltd. has an Innovation Score of 27.8 out of 100 (25th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Xigen Inflammation Ltd. focus on?

Xigen Inflammation Ltd.'s top technology area is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes) with 13 patents, ranking #1,747 of 7,163 assignees active in that subclass. Grants appear in 5 CPC subclasses total.

Is Xigen Inflammation Ltd.'s patent grant rate increasing or decreasing?

Xigen Inflammation Ltd.'s recent grant velocity is -37% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Xigen Inflammation Ltd.'s patents?

Xigen Inflammation Ltd.'s patents average 10.6 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Xigen Inflammation Ltd. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Xigen Inflammation Ltd.

USPTO PatentsView assignee record - 13 granted patents across 5 technology areas, recorded in grant years 2015–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61K (Preparations FOR Medical, Dental OR Toiletry Purposes).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Xigen ranks #22,052 of 49,997 tracked US assignees by granted-patent volume, with 13 patents across 5 technology areas.

#22,052
of 49,997 US assignees by volume: 25th percentile
by Innovation Score (27.8/100): 10.6
avg claims per patent: -37%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R22052 · Foreign Corporation #22,052 · 13 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-PAR · TYPE-FRNCORP · VEL-DOWN · BOOK-FULL

GRANTS-MICRO 13 grants
MID-PACK #22,052/49,997
PHOTO-FINISH Wrinkl
CPC-NARROW A61K · 5 areas
INNOV-THIN 27.8/100
CLAIMS-PAR 10.6 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DOWN -37% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Wrinkl, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Xigen’s 27.8 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 9.1 pts (33%) Velocity 4.4 pts (16%) Breadth 7.9 pts (28%) Claim depth 6.4 pts (23%)

Qualcomm Incorporated · highest

85
Xigen Inflammation · this assignee

28
3D Lighting… · lowest

7

What this shows Xigen's Innovation Score is 27.8/100 (25th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Xigen?

Each dot is one of Xigen’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Xigen’s own 10.6 claims/patent is at or below the 12.2 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Xigen vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Xigen's grants concentrate

Xigen Inflammation Ltd. is a focused PatentsView assignee: 5 CPC subclasses with 100% of grants classified under A61K (Preparations FOR Medical, Dental OR Toiletry Purposes). Peak complete grant year is 2015 (4 grants) versus a trough of 1 in 2016. By volume, Xigen sits between Wrinkl, Inc. and XRS Corporation.

Xigen's three-year grant acceleration

Xigen Inflammation Ltd. shows 2 grants in 2022–2024 against only 3 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Wrinkl

13
Wubbers

13
Xi'an Thermal Pow…

13
Xi'an ZTE NEW Sof…

13
XJ Group

13
Xmos

13
XR Reserve

13
XRS

13
Xigen Inflammation ◀

13

What this shows Xigen holds 13 patents at rank #22,046, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Xigen

By rank, the assignees closest to #22,046 in granted patent volume.

Leaders in A61K (Preparations FOR Medical)

Other assignees with the most granted patents in Xigen's primary technology class.

Xigen's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

28 25th percentile higher than 25% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Xigen Inflammation Ltd. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	4	30.8%
2016	1	7.7%
2017	2	15.4%
2018	1	7.7%
2020	2	15.4%
2021	1	7.7%
2022	1	7.7%
2023	1	7.7%

Which technologies does Xigen Inflammation Ltd. patent most?

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 13

C07K - Peptides 12

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 12

Y02A - Technologies FOR Adaptation TO Climate Change 8

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 4

Top 5 of 5 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Xigen Inflammation Ltd.'s patent record in context - here's where to go next.

Xigen Inflammation Ltd.'s lead technology class is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes), 100% of its portfolio - see every assignee active in that class. Explore A61K
Ranked #22,052 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Xigen Inflammation Ltd. against Wrinkl, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 27.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.